East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Brivaracetam Oral Solution, 10 mg/mL. Aurobindo Pharma’s Brivaracetam Oral Solution,  are an AB-rated generic equivalent to the reference listed drug (RLD), Briviact® Oral Solution, manufactured by UBC, Inc.

Brivaracetam Oral Solution are indicated for the:

• Treatment of partial-onset seizures in patients 1 month of age and older.